H.B. No. 2545

| 2 | relating to an individual's genetic data, including the use of that |
|----|--|
| 3 | data by certain genetic testing companies for commercial purposes |
| 4 | and the individual's property right in DNA; authorizing a civil |
| 5 | penalty. |
| 6 | BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: |
| 7 | SECTION 1. Subtitle A, Title 11, Business & Commerce Code, |
| 8 | is amended by adding Chapter 503A to read as follows: |
| 9 | CHAPTER 503A. DIRECT-TO-CONSUMER GENETIC TESTING COMPANIES; RIGHTS |
| 10 | REGARDING DNA |
| 11 | Sec. 503A.001. DEFINITIONS. In this chapter: |
| 12 | (1) "Biological sample" means a material part of the |
| 13 | human body, or a discharge or derivative part of the body, including |
| 14 | tissue, blood, urine, or saliva that is known to contain DNA. |
| 15 | (2) "Deidentified data" means data not reasonably |
| 16 | linked to and that cannot reasonably be used to infer information |
| 17 | about an identifiable individual. |
| 18 | (3) "Direct-to-consumer genetic testing company" |
| 19 | means an entity that: |
| 20 | (A) offers genetic testing products or services |
| 21 | directly to individuals as consumers of those products or services; |
| 22 | <u>or</u> |
| 23 | (B) collects, uses, or analyzes genetic data |
| 24 | that: |

AN ACT

1

| 1 | (i) results from a direct-to-consumer | | |
|----|---|--|--|
| 2 | genetic testing product or service; and | | |
| 3 | (ii) an individual rather than a health | | |
| 4 | care provider provides to the entity. | | |
| 5 | (4) "DNA" means deoxyribonucleic acid. | | |
| 6 | (5) "Express consent" means an individual's | | |
| 7 | affirmative response to a clear and meaningful notice regarding the | | |
| 8 | collection, use, or disclosure of genetic data for a specific | | |
| 9 | purpose. | | |
| 10 | (6) "Genetic data" means any data, regardless of | | |
| 11 | format, concerning an individual's genetic characteristics. The | | |
| 12 | term: | | |
| 13 | (A) includes: | | |
| 14 | (i) raw sequence data derived from | | |
| 15 | sequencing all or a portion of an individual's extracted DNA; | | |
| 16 | (ii) genotypic and phenotypic information | | |
| 17 | obtained from analyzing an individual's raw sequence data; and | | |
| 18 | (iii) health information regarding the | | |
| 19 | health conditions that an individual self-reports to a company and | | |
| 20 | that the company: | | |
| 21 | (a) uses for scientific research or | | |
| 22 | <pre>product development; and</pre> | | |
| 23 | (b) analyzes in connection with the | | |
| 24 | individual's raw sequence data; and | | |
| 25 | (B) does not include deidentified data. | | |
| 26 | (7) "Genetic testing" means a laboratory test of an | | |
| 27 | individual's complete DNA, regions of DNA, chromosomes, genes, or | | |

- 1 gene products to determine the presence of the individual's genetic
- 2 characteristics.
- 3 (8) "Person" means an individual, partnership,
- 4 corporation, association, business, or business trust or the legal
- 5 representative of an organization.
- 6 Sec. 503A.002. APPLICABILITY. (a) This chapter applies to
- 7 <u>a direct-to-consumer genetic testing company that:</u>
- 8 <u>(1) offers its products or services to individuals who</u>
- 9 are residents of this state; or
- 10 (2) collects, uses, or analyzes genetic data that:
- 11 (A) results from the company's products or
- 12 services; and
- 13 (B) was provided to the company by an individual
- 14 who is a resident of this state rather than by or at the direction of
- 15 <u>a health care provider.</u>
- (b) This chapter does not apply to:
- 17 (1) an entity only when they are engaged in
- 18 collecting, using, or analyzing genetic data or biological samples
- 19 in the context of research, as defined by 45 C.F.R. Section 164.501,
- 20 that is conducted in accordance with:
- 21 (A) the federal policy for the protection of
- 22 <u>human subjects (45 C.F.R. Part 46);</u>
- 23 (B) the good clinical practice guidelines issued
- 24 by the International Council for Harmonisation of Technical
- 25 Requirements for Pharmaceuticals for Human Use (ICH); or
- 26 (C) the United States Food and Drug
- 27 Administration policy for the protection of human subjects (21

- 1 C.F.R. Parts 50 and 56);
- 2 (2) genetic data that is protected health information
- 3 collected by a covered entity or business associate, as defined by
- 4 45 C.F.R. Part 160, subject to the privacy, security, and breach
- 5 notification rules under the Health Insurance Portability and
- 6 Accountability Act of 1996 (42 U.S.C. Section 1320d et seq.);
- 7 (3) an institution of higher education or a private or
- 8 independent institution of higher education, as those terms are
- 9 defined by Section 61.003, Education Code;
- 10 (4) an entity when the entity is offering genetic
- 11 testing products or services through a health care provider; or
- 12 (5) the collection, use, or analysis of genetic data
- 13 by a health care provider.
- 14 Sec. 503A.003. EXCLUSIVE PROPERTY RIGHT IN DNA;
- 15 CONFIDENTIALITY. An individual has a property right in, and
- 16 retains the right to exercise exclusive control over, the
- 17 individual's biological sample that is provided to or used by a
- 18 direct-to-consumer genetic testing company and the results of
- 19 genetic testing or analysis conducted on the individual's DNA by a
- 20 direct-to-consumer genetic testing company, including to the
- 21 collection, use, retention, maintenance, disclosure, or
- 22 destruction of the sample or results. The results of the genetic
- 23 testing of an individual's DNA are confidential and may not be
- 24 disclosed to another person without the individual's express
- 25 consent.
- Sec. 503A.004. REQUIREMENTS FOR CERTAIN USES OF
- 27 DEIDENTIFIED DATA. (a) Except as otherwise provided by this

- 1 chapter or other law, a direct-to-consumer genetic testing company
- 2 that possesses an individual's deidentified data shall:
- 3 (1) implement administrative and technical measures
- 4 to ensure the data is not associated with a particular individual;
- 5 and
- 6 (2) publicly commit to maintaining and using data in
- 7 deidentified form and refraining from making any attempt to
- 8 identify an individual using the individual's deidentified data.
- 9 (b) If a direct-to-consumer genetic testing company shares
- 10 an individual's deidentified data with another person, the company
- 11 shall enter into a legally enforceable contractual obligation
- 12 prohibiting the person from attempting to identify an individual
- 13 using the individual's deidentified data.
- 14 Sec. 503A.005. REQUIREMENTS FOR CERTAIN USES OR DISCLOSURE
- 15 OF GENETIC DATA AND BIOLOGICAL SAMPLE. (a) A direct-to-consumer
- 16 genetic testing company shall:
- 17 (1) develop, implement, and maintain a comprehensive
- 18 security program to protect an individual's genetic data against
- 19 unauthorized access, use, or disclosure; and
- 20 (2) make publicly available:
- 21 (A) a high-level privacy policy overview that
- 22 <u>includes</u> basic, essential information about the company's
- 23 <u>collection</u>, use, or disclosure of genetic data; and
- 24 (B) a prominent privacy notice that includes
- 25 information about the company's data collection, consent, use,
- 26 access, disclosure, transfer, security, retention, and deletion
- 27 practices.

(b) Before collecting, using, or disclosing an individual's 1 2 genetic data, a direct-to-consumer genetic testing company shall provide to the individual information about the company's 3 collection, use, and disclosure of genetic data the company 4 5 collects through a genetic testing product or service, including 6 information that: 7 (1) clearly describes the company's use of the genetic 8 data; 9 (2) specifies the persons who have access to test 10 results; and (3) specifies the manner in which the company may 11 12 share the genetic data. (c) A direct-to-consumer genetic testing company shall 13 14 provide a process for an individual to: 15 (1) access the individual's genetic data; 16 (2) delete the individual's account and genetic data; 17 and (3) destroy or require the destruction of the 18 19 individual's biological sample. Sec. 503A.006. REQUIRED CONSENT. (a) A direct-to-consumer 20 genetic testing company engaging in any of the following activities 21 22 must obtain: 23 (1) an individual's separate express consent for: (A) the transfer or disclosure of 24 25 individual's genetic data to any person other than the company's 26 vendors and service providers;

(B) the use of genetic data for a purpose other

27

(a)

1 than the primary purpose of the company's genetic testing product 2 or service; or (C) the retention of any biological sample 3 provided by the individual following the company's completion of 4 5 the initial testing service requested by the individual; 6 (2) an individual's informed consent in accordance 7 with guidelines for the protection of human subjects issued under 45 C.F.R. Part 46, for transfer or disclosure of the individual's 8 genetic data to a third party for: 9 10 (A) research purposes; or (B) research conducted under the control of the 11 12 company for the purpose of publication or generalizable knowledge; 13 and 14 (3) an individual's express consent for: (A) marketing by the company to the individual 15 based on the individual's genetic data; or 16 17 (B) marketing by a third party to the individual based on the individual's ordering or purchasing of a genetic 18 19 testing product or service. (b) For purposes of Subsection (a), "marketing" does not 20 include providing customized content or offers to an individual 21 with whom a direct-to-consumer genetic testing company has a 22 first-party relationship on the company's Internet website or 23 24 through an application or service provided by the company to the individual. 25

direct-to-consumer genetic testing company may not disclose an

Sec. 503A.007. PROHIBITED DISCLOSURES.

26

27

- 1 individual's genetic data to a law enforcement entity or other
- 2 governmental body unless:
- 3 (1) the company first obtains the individual's express
- 4 written consent; or
- 5 (2) the entity or body obtains a warrant or complies
- 6 with another valid legal process required by the company.
- 7 (b) A direct-to-consumer genetic testing company may not
- 8 disclose, without first obtaining an individual's written consent,
- 9 the individual's genetic data to:
- 10 (1) an entity that offers health insurance, life
- 11 insurance, or long-term care insurance; or
- 12 (2) an employer of the individual.
- Sec. 503A.008. CIVIL PENALTY. (a) A direct-to-consumer
- 14 genetic testing company that violates this chapter is liable to
- 15 this state for a civil penalty in an amount not to exceed \$2,500 for
- 16 each violation.
- 17 (b) The attorney general may bring an action to recover a
- 18 civil penalty imposed under Subsection (a) and to restrain and
- 19 enjoin a violation of this chapter. The attorney general may
- 20 recover reasonable attorney's fees and court costs incurred in
- 21 bringing the action.
- 22 SECTION 2. The changes in law made by this Act apply only to
- 23 genetic information obtained on or after the effective date of this
- 24 Act.
- 25 SECTION 3. This Act takes effect September 1, 2023.

H.B. No. 2545

| President of the Senate | Speaker of the House | | | |
|--|----------------------------------|--|--|--|
| I certify that H.B. No. 2545 | was passed by the House on April | | | |
| 28, 2023, by the following vote: | Yeas 144, Nays 0, 2 present, not | | | |
| voting; and that the House concurred in Senate amendments to H.B. | | | | |
| No. 2545 on May 17, 2023, by the following vote: Yeas 146, Nays 0, | | | | |
| 1 present, not voting. | | | | |
| | | | | |
| | Chief Clerk of the House | | | |
| I certify that H.B. No. 254 | 5 was passed by the Senate, with | | | |
| amendments, on May 15, 2023, by th | e following vote: Yeas 31, Nays | | | |
| 0. | | | | |
| | | | | |
| | Secretary of the Senate | | | |
| APPROVED: | | | | |
| Date | | | | |
| | | | | |
| | | | | |
| Governor | | | | |